Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

Fresenius Medical Care (FME) named Shervin J Korangy as its new CEO and management board chair, effective October 12. Korangy brings healthcare and life sciences leadership experience, previously serving as CEO of BVI Medical. Fresenius Medical Care operates 3,513 dialysis clinics worldwide. Shares have traded between €34.57 and €47.86 over the past year, closing at €37.42 on Wednesday.

NIO reported 4,165 battery swap stations and 5,376 charging stations in China, with 86.7% of energy delivered to non-NIO vehicles. The company aims to add 1,000 swap stations this year, with Geely Holding Group investing $2.4B in NIO Power. Onvo, a partner brand, has launched new models and expanded service centers. Retail investors on Stocktwits expressed bullish sentiment, with NIO shares down 31% YTD.

Equinor discovered gas at the Gullfaks field, which could sustain production. The well was drilled as part of a production well project. Equinor, Petoro, and OMV hold the license.

Dan Ives, a partner at Yorkville Ives, named Nvidia, Microsoft, Palantir, Apple, and CrowdStrike as his top tech stock picks for 2027. He highlighted a $4 trillion AI spending wave and set price targets: Nvidia ($300), Microsoft ($615), Palantir ($250), Apple ($400), and CrowdStrike ($335). The stocks have varied performance in 2026, with CrowdStrike up 126.50% and others showing modest gains.

Lululemon Athletica (LULU) has appointed Maggie Gauger as President and Chief Product Officer and Joseph Godsey as Chief Operating Officer. The changes are part of a broader leadership shake-up, with several senior executives departing. Analysts expect stable earnings of about US$1.4b and modestly lower profit margins around 12.4% over the next few years.